Predictors of patient response to treatment with EGF receptor inhibitors
摘要
<p>The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.</p>
申请公布号
EP2615183(A1)
申请公布日期
2013.07.17
申请号
EP20130163561
申请日期
2009.05.13
申请人
GENOMIC HEALTH, INC.;BRISTOL-MYERS SQUIBB COMPANY
发明人
BAKER, JOFFRE;WATSON, DREW;MADDALA, TARA;SHAK, STEVEN;MAURO, DAVID, J.;FORD, SHIRIN, K.